Monoclonal antibodies imaging agents

Subramanian, R., and Meares, C.F. (1991) Bifunctional chelating agents for radiometal-labeled monoclonal antibodies. In Cancer Imaging with Radiolabeled Antibodies (D.M. Coldenberg, ed.), pp. 183-199. Kluwer, Boston, MA. 

The use of MCAs is by no means restricted to radiopharmacy. Brady et al.222 have exploited this technique by using as a contrast agent Mn2+ bound by DTPA immobilized on the monoclonal antibody antimyosin. The extent of infarcted myocardium was determined with 2 mg of antibody bearing 50 qg Mn2+. It is to be expected that many more similar contrast agents await development. Their development will extend magnetic resonance imaging. 

The following discussion is focused on in vitro applications of monoclonal antibodies and nucleic acid probes as diagnostic reagents. The principles of production and characteristics of Mabs are described in Chapter 2. Their use as in vivo diagnostic imaging agents has been discussed in Chapter 3 in the context of therapeutic applications, and is not discussed further here. The principles of PCR and nucleic acid hybridization have been discussed in Chapter 2 and Chapter 4, respectively. 

Muzykantov V. and Danilov, S. (1995) Targeting of radiolabeled monoclonal antibody against ACE to the pulmonary endothelium, in Targeted Delivery of Imaging Agents (Torchilin, V., ed.), CRC, Boca Ration, FL, pp. 465 485. 

---